Ken Griffin Annovis Bio, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 48,600 shares of ANVS stock, worth $128,790. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,600
Previous 15,000
224.0%
Holding current value
$128,790
Previous $75,000
4.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ANVS
# of Institutions
55Shares Held
2.09MCall Options Held
88.1KPut Options Held
188K-
Vanguard Group Inc Valley Forge, PA648KShares$1.72 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY166KShares$440,4800.0% of portfolio
-
Ubs Group Ag161KShares$426,3210.0% of portfolio
-
Geode Capital Management, LLC Boston, MA153KShares$404,4240.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA128KShares$338,4180.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $21.6M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...